Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000470813 | SCV000541969 | likely benign | Neurofibromatosis, type 1 | 2024-09-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002318497 | SCV000666598 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-08-24 | criteria provided, single submitter | clinical testing | The c.4514+3A>G intronic variant results from an A to G substitution 3 nucleotides after coding exon 33 in the NF1 gene. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing; however, direct evidence is insufficient at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000470813 | SCV002560445 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |